President and CEO Ned McCoy shared with Becker's some of the company's key objectives for the year, including the launch of some of the first medications from its Petersburg, Va.-based plant, the ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...

South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.

Biocon Biologics on Thursday said it has tied up with not-for-profit generic drug and pharmaceutical firm Civica, Inc to expand access and affordability of Insulin Aspart in the US.

The 26-week, open-label clinical trial randomized 230 pediatric subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...